Drug intelligence / Profile preview

R-BL-M-04

Development stage: Phase 3
Lead developer: National Research Center for Hematology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

**R-BL-M-04** is an intensive rituximab-containing multi-agent chemotherapy regimen derived from the Russian **BL-M-04** protocol. It combines the anti-CD20 monoclonal antibody rituximab with alternating intensive chemotherapy blocks and has been evaluated for newly diagnosed high-grade B-cell lymphoma, including double-hit high-grade B-cell lymphoma and high-grade B-cell lymphoma not otherwise specified. The regimen is also related to the BL-M-04 protocol previously reported for Burkitt lymphoma.

Other names: LB-M-04 + rituximab

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on R-BL-M-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R-BL-M-04.

Explore the full profile